PROTECTIVE ACTIVITY OF NOVEL BENZIMIDAZOLE DERIVATIVES AT EXPERIMENTAL INFLUENZA INFECTION

Cover Page

Cite item

Abstract

Influenza is an acute respiratory viral infection, which represents an important health problem. Every year, influenza causes epidemics  and pandemics, leading to increase in morbidity and mortality in all  regions of the globe. Due to the segmental organization of the  genome and low accuracy of its replication, the influenza virus is  capable of escaping the host’s immune response (antigenic drift), as  well as the selection of drug-resistant variants. This calls for  constant monitoring of the sensitivity of viral isolates to antiviral  drugs and the development of new etiotropic antiviral agents that  have alternative targets and mechanisms of activity. The purpose of  this study was to characterize the new aminobenzimidazole  derivatives as protective agents in lethal influenza infection in white  mice. The efficacy of the compounds was assessed by their ability to  reduce specific mortality of animals in the course of lethal influenza  pneumonia caused by the influenza A/Puerto Rico/8/34 (H1N1)  irus, increase the life duration of animals, and normalize the  morphological structure of lung tissue comparing to the placebo  group. For all the compounds studied, a decrease in the specific  mortality of animals (from 20 to 60%) has been shown. The  reference drug (oseltamivir phosphate) reduced the mortality of  mice by 80%. The benzimidazole derivative 2519 demonstrated the  highest indices of protective activity, its use reduced the mortality of  animals by 60% and increased their mean day of death by 1.6 days in comparison with the control group. Morphological analysis showed that the activity of derivative 2519 was manifested in the  normalization of the morphological structure of lung tissue in the  course of influenza pneumonia. On day 5 after infection, the cells of  the bronchial epithelium looked intact, in contrast to destroyed cells  with numerous viral inclusions in control animals. The foci of  inflammation themselves occupied a smaller area compared to the  control. At the same time, there was no correlation between the  previously obtained data on the virus-inhibiting effect of these  compounds in vitro and the data obtained in animals. This suggests  that despite the presence of direct antiviral activity detected  previously in in vitro experiments, the protective properties of the  studied aminobenzimidazoles on animals are caused, in addition to  the etiotropic effect, by other pathogenetic factors. In conclusion,  amino derivatives of benzimidazole should be considered as  compounds that are promising for further development and  introduction as an anti-influenza agents. 

About the authors

V. V. Zarubaev

St. Petersburg Pasteur Institute

Author for correspondence.
Email: zarubaev@gmail.com

PhD (Medicine), Senior Researcher, Laboratory of Experimental Virology, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation

197101, Russian Federation, St. Petersburg, Mira str., 14

Phone: +7 (911) 928-04-95 Fax: +7 (812) 233-20-92

Russian Federation

S. V. Vasilieva

Institute of Chemical Biology and Fundamental Medicine, RAS (Siberian Branch)

Email: fake@neicon.ru

PhD (Chemistry), Researcher, Laboratory of Chemistry of Nucleic Acids, Novosibirsk, Russian Federation

Russian Federation

Y. L. Esaulkova

St. Petersburg State University

Email: fake@neicon.ru

Student, St. Petersburg State University, St. Petersburg, Russian Federation

Russian Federation

A. V. Garshinina

St. Petersburg Pasteur Institute

Email: fake@neicon.ru

Researcher, Laboratory of Experimental Virology, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation

Russian Federation

V. M. Veprintseva

St. Petersburg Veterinary Academy

Email: fake@neicon.ru

Student, Saint Petersburg Veterinary Academy, St. Petersburg, Russian Federation

Russian Federation

A. V. Galochkina

St. Petersburg Pasteur Institute

Email: fake@neicon.ru

PhD (Medicine), Junior Researcher, Laboratory of Experimental Virology, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation

Russian Federation

Y. S. Protsak

1st St.Petersburg Medical University

Email: fake@neicon.ru

Student, First Pavlov State Medical University, St. Petersburg, Russian Federation

Russian Federation

I. V. Teselkin

St. Petersburg Technological Institute (Technical University)

Email: fake@neicon.ru

Student, St. Petersburg State Technological Institute (Technical University), St. Petersburg, Russian Federation

Russian Federation

A. S. Morkovnik

Southern Federal University

Email: fake@neicon.ru

PhD, MD (Chemistry), Head of the Laboratory of Organic Synthesis, Southern Federal University, Rostov-on-Don, Russian Federation

Russian Federation

L. N. Divaeva

Southern Federal University

Email: fake@neicon.ru

PhD (Chemistry), Senior Researcher, Laboratory of Organic Synthesis, Southern Federal University, Rostov-on-Don, Russian Federation

Russian Federation

I. N. Lavrentieva

St. Petersburg Pasteur Institute

Email: fake@neicon.ru

PhD, MD (Biology), Head of the Laboratory of Experimental Virology, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation

Russian Federation

References

  1. Abed Y., Goyette N., Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother., 2005, vol. 49, no. 2, pp. 556–559. doi: 10.1128/AAC.49.2.556-559.2005
  2. Akhtar W., Khan M.F., Verma G., Shaquiquzzaman M., Rizvi M.A., Mehdi S.H., Akhter M., Alam M.M. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. Eur. J. Med. Chem., 2017, vol. 126, pp. 705–753. doi: 10.1016/j.ejmech.2016.12.010
  3. Beesu M., Caruso G., Salyer A.C., Shukla N.M., Khetani K.K., Smith L.J., Fox L.M., Tanji H., Ohto U., Shimizu T., David S.A. Identification of a human toll-like receptor (TLR) 8-specific agonist and a functional pan-TLR inhibitor in 2-aminoimidazoles. J. Med. Chem., 2016, vol. 59, no. 7, pp. 3311–3330. doi: 10.1021/acs.jmedchem.6b00023
  4. Cady S.D., Schmidt-Rohr K., Wang J., Soto C.S., Degrado W.F., Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature, 2010, vol. 463, pp. 689–692. doi: 10.1038/nature08722
  5. Cichero E., Tonelli M., Novelli F., Tasso B., Delogu I., Loddo R., Bruno O., Fossa P. Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles. J. Enzyme Inhib. Med. Chem., 2017, vol. 32, no. 1, pp. 375–402. doi: 10.1080/14756366.2016.1256881
  6. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., Bresee J.S., Cox N.J. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep., 2008, vol. 57, pp. 1–60.
  7. Hurt A.C. The epidemiology and spread of drug resistant human influenza viruses. Curr. Opin. Virol., 2014, vol. 8, pp. 22–29. doi: 10.1016/j.coviro.2014.04.009
  8. Ikematsu H., Kawai N., Iwaki N., Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013–2014 season. J. Infect. Chemother., 2015, vol. 21, iss. 9, pp. 634–638. doi: 10.1016/j.jiac.2015.05.004
  9. Keri R.S., Hiremathad A., Budagumpi S., Nagaraja B.M. Comprehensive review in current developments of benzimidazole-based medicinal chemistry. Chem. Biol. Drug Des., 2015, vol. 86, iss. 1, pp. 19–65. doi: 10.1111/cbdd.12462
  10. Kharitonova M.I., Denisova A.O., Andronova V.L., Kayushin A.L., Konstantinova I.D., Kotovskaya S.K., Galegov G.A., Charushin V.N., Miroshnikov A.I. New modified 2- aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1. Bioorg. Med. Chem. Lett., 2017, vol. 27, iss. 11, pp. 2484–2487. doi: 10.1016/j.bmcl.2017.03.100
  11. Kim M.K., Shin H., Park K.S., Kim H., Park J., Kim K., Nam J., Choo H., Chong Y. Benzimidazole derivatives as potent JAK1-selective inhibitors. J. Med. Chem., 2015, vol. 58, no. 18, pp. 7596–7602. doi: 10.1021/acs.jmedchem.5b01263
  12. Lee S.M., Yen H.L. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res., 2012, vol. 96, iss. 3, pp. 391–404. doi: 10.1016/j.antiviral.2012.09.013
  13. Pécheur E.I., Borisevich V., Halfmann P., Morrey J.D., Smee D.F., Prichard M., Mire C.E., Kawaoka Y., Geisbert T.W., Polyak S.J. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J. Virol., 2016, vol. 90, no. 6, pp. 3086–3092. doi: 10.1128/JVI.02077-15
  14. Samson M., Pizzorno A., Abed Y., Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res., 2013, vol. 98, iss. 2, pp. 174–185. doi: 10.1016/j.antiviral.2013.03.014
  15. Scholtissek C., Quack G., Klenk H.D., Webster R.G. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res., 1998, vol. 37, iss. 2, pp. 83–95. doi: 10.1016/S0166-3542(97)00061-2
  16. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-García J., Lazzarin A., Carosi G., Sasadeusz J., Katlama C., Montaner J., Sette H.Jr., Passe S., De Pamphilis J., Duff F., Schrenk U.M., Dieterich D.T., APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 2004, vol. 351, pp. 438–450. doi: 10.1056/NEJMoa040842
  17. Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann. N. Y. Acad. Sci., 2014, vol. 1323, 115–139. doi: 10.1111/nyas.12462
  18. Zarubaev V.V., Morkovnik A.S., Divaeva L.N., Karpinskaya L.A., Borodkin G.S. Tautomeric and non-tautomeric N-substituted 2-iminobenzimidazolines as new lead compounds for the design of anti-influenza drugs: an in vitro study. Bioorg. Med. Chem., 2016, vol. 24, iss. 22, pp. 5796–5803. doi: 10.1016/j.bmc.2016.09.036

Copyright (c) 2018 Zarubaev V.V., Vasilieva S.V., Esaulkova Y.L., Garshinina A.V., Veprintseva V.M., Galochkina A.V., Protsak Y.S., Teselkin I.V., Morkovnik A.S., Divaeva L.N., Lavrentieva I.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies